A Phase 3 interventional study of docetaxel, doxorubicin, cyclophosphamide and Docetaxel,doxorubicin, cyclophosphamide in Breast Cancer, sponsored by Sanofi. Completed at 37 sites in 37 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-12-30.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.
Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 5th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2001, is one of 51 in phase 3, and was the 106th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai JMT-Bio Inc. · Sites in China
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 178 · Phase 3 55 · Phase 4 5
First in 1993; this study’s year is marked. 13 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,299 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 248 interventional studies. Of the 207 that completed or were terminated, 58 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 264 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
40 studies in Breast Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 39 finished, 14 (36%) have results posted.
Among the 40 studies in Breast Neoplasms by Sanofi, this one has the largest enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2001, is one of 11 in phase 3, and was the 8th registered.
Sanofi’s Breast Neoplasms studies by the year they started, since 1994.
3 of the studies testing docetaxel in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747338Phase 3Shanghai JMT-Bio Inc.A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | 2026-12-16 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 264 studies testing docetaxel in Breast Neoplasms, from their registry updates:
Among Sanofi’s 40 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective :
Secondary objectives :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Laboratory requirements: (within 14 days prior to registration)
Hematology:
Hepatic function:
Renal function:
Exclusion Criteria :
Other serious illness or medical condition:
Past or current history of neoplasm other than breast carcinoma, except for:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -\> T)
Drug: Docetaxel,doxorubicin, cyclophosphamide
Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
Drug: docetaxel, doxorubicin, cyclophosphamide
Drug pages: Docetaxel · Doxorubicin · Cyclophosphamide
TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
Drug pages: Docetaxel · Doxorubicin · Cyclophosphamide
AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)
The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame: Median follow-up 65 months
Death From Any Cause (Overall Survival)
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame: Median follow-up of 65 months
| Milestone | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) |
|---|---|---|
| Started | 1649 | 1649 |
| Completed | 1477 | 1526 |
| Not completed | 172 | 123 |
| Withdrew: Adverse event | 97 | 61 |
| Withdrew: Protocol violation | 5 | 3 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lack of efficacy | 7 | 4 |
| Withdrew: Lost to follow-up | 3 | 5 |
| Withdrew: Withdrawal by subject | 53 | 42 |
| Withdrew: Other | 5 | 7 |
The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
| Participants | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) |
|---|---|---|
| Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) | 356 | 352 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
| Participants | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) |
|---|---|---|
| Death From Any Cause (Overall Survival) | 187 (65.64 to 65.91) | 202 (65.48 to 65.84) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | — | 331/1,634 (20.3%) | 1,634/1,634 (100%) |
| Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | — | 520/1,635 (31.8%) | 1,629/1,635 (99.6%) |
| Event | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) |
|---|---|---|
| Fever (including serious febrile neutropenia)General disorders | 122/1634 | 293/1635 |
| Infection (including neutropenic infection)Infections and infestations | 86/1634 | 143/1635 |
| LeukopeniaBlood and lymphatic system disorders | 18/1634 | 56/1635 |
| VomitingGastrointestinal disorders | 16/1634 | 28/1635 |
| NauseaGastrointestinal disorders | 14/1634 | 19/1635 |
| Thrombophlebitis DeepVascular disorders | 14/1634 | 14/1635 |
| DiarrheaGastrointestinal disorders | 13/1634 | 13/1635 |
| StomatitisGastrointestinal disorders | 8/1634 | 9/1635 |
| DehydrationMetabolism and nutrition disorders | 8/1634 | 6/1635 |
| Derm ExfoliatingSkin and subcutaneous tissue disorders | 8/1634 | 1/1635 |
| Event | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 1601/1634 | 1587/1635 |
| NauseaGastrointestinal disorders | 1435/1634 | 1334/1635 |
| AstheniaMusculoskeletal and connective tissue disorders | 1328/1634 | 1310/1635 |
| NeutropeniaBlood and lymphatic system disorders | 1133/1634 | 1049/1635 |
| StomatitisGastrointestinal disorders | 1035/1634 | 1026/1635 |
| VomitingGastrointestinal disorders | 907/1634 | 742/1635 |
| MyalgiaMusculoskeletal and connective tissue disorders | 834/1634 | 587/1635 |
| Nail disorderSkin and subcutaneous tissue disorders | 729/1634 | 363/1635 |
| NeuropathyNervous system disorders | 723/1634 | 482/1635 |
| AnemiaBlood and lymphatic system disorders | 461/1634 | 658/1635 |
| Age, Customized(Participants) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| > =65 years | 85 | 83 | 168 |
| Between 65 and 50 years | 784 | 783 | 1567 |
| Between 49 and 35 years | 689 | 710 | 1399 |
| < =35 years | 91 | 73 | 164 |
| Age, Continuous(years) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| Median | 50 (22 to 74) | 50 (24 to 72) | 50 (22 to 74) |
| Sex: Female, Male(Participants) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| Female | 1649 | 1649 | 3298 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| Argentina | 31 | 32 | 63 |
| Australia | 156 | 144 | 300 |
| Belgium | 33 | 31 | 64 |
| Bosnia And Herzegovina | 5 | 5 | 10 |
| Brazil | 19 | 21 | 40 |
| Bulgaria | 11 | 11 | 22 |
| Canada | 174 | 180 | 354 |
| China | 21 | 17 | 38 |
| Colombia | 6 | 8 | 14 |
| Croatia | 29 | 29 | 58 |
| Cyprus | 2 | 5 | 7 |
| Czech Republic | 11 | 10 | 21 |
| Egypt | 4 | 4 | 8 |
| Estonia | 3 | 2 | 5 |
| France | 59 | 58 | 117 |
| Germany | 224 | 223 | 447 |
| Greece | 5 | 3 | 8 |
| Hong Kong | 3 | 6 | 9 |
| Hungary | 34 | 35 | 69 |
| Ireland | 83 | 88 | 171 |
| Israel | 63 | 67 | 130 |
| Lebanon | 23 | 18 | 41 |
| Mexico | 5 | 3 | 8 |
| New Zealand | 21 | 19 | 40 |
| Poland | 167 | 168 | 335 |
| Portugal | 2 | 1 | 3 |
| Russian Federation | 32 | 35 | 67 |
| Romania | 17 | 19 | 36 |
| Saudi Arabia | 2 | 0 | 2 |
| Slovenia | 15 | 17 | 32 |
| South Africa | 19 | 21 | 40 |
| South Korea | 22 | 27 | 49 |
| Spain | 26 | 41 | 67 |
| Taiwan | 18 | 16 | 34 |
| United States | 294 | 278 | 572 |
| Uruguay | 4 | 2 | 6 |
| Venezuela | 6 | 5 | 11 |
| Hormonal Receptor Status(Participants) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| Positive | 1348 | 1346 | 2694 |
| Negative | 301 | 303 | 604 |
| Karnofsky Performance Status at Baseline(Participants) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| 80 - Activity with effort; some signs of disease | 36 | 33 | 69 |
| 90 - Normal activity; minor signs of disease | 315 | 323 | 638 |
| 100 - Normal no complaints; no evidence of disease | 1298 | 1293 | 2591 |
| Menopausal status(Participants) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| Pre-Menopausal or Other age < 50 Years | 866 | 863 | 1729 |
| Post-Menopausal or Other age > 50 Years | 783 | 786 | 1569 |
| Number of Positive Lymph Nodes(Participants) | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | Total |
|---|---|---|---|
| [0] | 0 | 1 | 1 |
| [1 to 3] | 1010 | 1005 | 2015 |
| [4 to 10] | 462 | 456 | 918 |
| > 10 | 177 | 187 | 364 |
2 further baseline measures are reported on the registry.
The record gives a start of Nov 2001, a primary completion of Oct 2008 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Doxorubicin · Cyclophosphamide